All In Biotech

NDA 020226 · Alcon

Naphcon-A

Naphazoline Hydrochloride, Pheniramine Maleate · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Dec 19, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

Jun 8, 1994

Approved uses

1

Original approval plus efficacy supplements

Registered trials

8

4 Phase 3, 0 recruiting

FAERS reports

295

28 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 27, 2024.

Uses for the temporary relief of redness and itching of the eye(s) due to: ragweed pollen grass animal dander and hair

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 8, 1994 Original approval · Type 4 - New Combination
1 products under this application
  • NAPHCON-A · NAPHAZOLINE HYDROCHLORIDE 0.025%; PHENIRAMINE MALEATE 0.3% · SOLUTION/DROPS, OPHTHALMIC · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Naphazoline" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective126
  • eye irritation55
  • eye pain27
  • ocular hyperaemia22
  • mydriasis20
  • vision blurred19
  • dry eye12
  • headache11
  • dizziness10
  • eye pruritus10
  • fatigue9
  • nausea9

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20132
20145
201510
201631
201752
201888
20199
202017
202129
202212
20238
202410
202513
20269

Recalls

1 FDA enforcement reports for this application.

  • Jun 29, 2022 · Class II · Terminated

    CGMP Deviations: products were stored outside the drug label specifications.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 25 on PubMed

Sponsor: Alcon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.